---
figid: PMC3238080__npp2011198f2
figtitle: Regulation of intracellular signaling by antiepileptics and modulators of
  glutamate, acetylcholine, and melatonin systems
organisms:
- NA
pmcid: PMC3238080
filename: npp2011198f2.jpg
figlink: /pmc/articles/PMC3238080/figure/fig2/
number: F2
caption: Regulation of intracellular signaling by antiepileptics and modulators of
  glutamate, acetylcholine, and melatonin systems. The antiepileptic drugs are either
  sodium channel blockers or have a direct effect on AMPA receptors. Ketamine is an
  antagonist of NMDA receptors. Activation of inotropic glutamate receptors increases
  intracellular sodium and calcium to regulate downstream protein kinases such as
  CaMK, Akt, and Erk. Blocking NMDA receptors by ketamine can induce the activation
  of Akt, which activates the mTOR pathway and inhibits GSK3. Ketamine also increases
  BDNF synthesis induced by elongation factor-2. Nicotine activates and mecamylamine
  blocks nicotinic acetylcholine receptors; scopolamine is an antagonist of muscarinic
  receptors; and agomelatine activates melatonin receptors. Metabolic glutamate, muscarinic
  acetylcholine, and melatonin receptors regulate G-protein-coupled signaling pathways
  such as PKA, PKC, and CaMK. AMPA, 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic
  acid receptor; BDNF, brain-derived neurotrophic factor; CaMK, calcium/calmodulin-dependent
  protein kinase; eEF2, elongation factor-2; mAch, muscarinic acetylcholine receptor;
  mGlu, metabolic glutamate receptor; MT, melatonin receptor; mTOR, mammalian target
  of rapamycin; nAch, nicotinic acetylcholine receptor; NaCh, sodium channel; NMDA,
  N-methyl--aspartic acid receptor.
papertitle: Review of Pharmacological Treatment in Mood Disorders and Future Directions
  for Drug Development.
reftext: Xiaohua Li, et al. Neuropsychopharmacology. 2012 Jan;37(1):77-101.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9584802
figid_alias: PMC3238080__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC3238080__F2
ndex: d1735402-dee3-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3238080__npp2011198f2.html
  '@type': Dataset
  description: Regulation of intracellular signaling by antiepileptics and modulators
    of glutamate, acetylcholine, and melatonin systems. The antiepileptic drugs are
    either sodium channel blockers or have a direct effect on AMPA receptors. Ketamine
    is an antagonist of NMDA receptors. Activation of inotropic glutamate receptors
    increases intracellular sodium and calcium to regulate downstream protein kinases
    such as CaMK, Akt, and Erk. Blocking NMDA receptors by ketamine can induce the
    activation of Akt, which activates the mTOR pathway and inhibits GSK3. Ketamine
    also increases BDNF synthesis induced by elongation factor-2. Nicotine activates
    and mecamylamine blocks nicotinic acetylcholine receptors; scopolamine is an antagonist
    of muscarinic receptors; and agomelatine activates melatonin receptors. Metabolic
    glutamate, muscarinic acetylcholine, and melatonin receptors regulate G-protein-coupled
    signaling pathways such as PKA, PKC, and CaMK. AMPA, 2-amino-3-(5-methyl-3-oxo-1,2-
    oxazol-4-yl) propanoic acid receptor; BDNF, brain-derived neurotrophic factor;
    CaMK, calcium/calmodulin-dependent protein kinase; eEF2, elongation factor-2;
    mAch, muscarinic acetylcholine receptor; mGlu, metabolic glutamate receptor; MT,
    melatonin receptor; mTOR, mammalian target of rapamycin; nAch, nicotinic acetylcholine
    receptor; NaCh, sodium channel; NMDA, N-methyl--aspartic acid receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - na
  - Nacalpha
  - ca
  - achi
  - emc
  - Nmdar1
  - mit
  - Tom40
  - Nach
  - ac
  - bt
  - norpA
  - Erk7
  - rl
  - Dg
  - AP-1gamma
  - Cam
  - CaMKII
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - eEF2
  - CG4849
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Pdk
  - Pdk1
  - Akt
  - NACA
  - FGFR3
  - CASP8
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - EPHB2
  - MAPK1
  - MAPK3
  - CALM1
  - CALM2
  - CALM3
  - KRIT1
  - CAMKMT
  - CAMK4
  - CAMK2G
  - CAMK1
  - CAMK1D
  - CAMK1G
  - CAMK2A
  - CAMK2B
  - CAMK2D
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - EEF2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PDK1
  - PDK2
  - PDK3
  - PDK4
  - AKT1
  - AKT2
  - AKT3
  - BDNF
  - BDNF-AS
  - Scopolamine Agomelatine
  - Carbamazepine
  - Ketamine
  - Mecamylamine
  - Nicotine
  - Valproic acid
  - AMPA
---
